The Biology and Clinical Features of Non-small Cell Lung Cancers with EML4-ALK Translocation

Overview

Journal Curr Oncol Rep

Publisher Current Science

Specialty Oncology

Date 2012 Feb 8

PMID 22311682

Citations 15

Authors

Rathi N Pillai

Suresh S Ramalingam

Affiliations

Soon will be listed here.

Abstract

The anaplastic lymphoma kinase (ALK) acts as a dominant oncogenic driver following chromosomal rearrangements in certain cancers including non-small cell lung cancer (NSCLC). NSCLC with ALK translocation occurs in a specific subset of patients and results in unique clinical features. Crizotinib is a small molecule inhibitor of ALK kinase that has recently been approved by the FDA for the treatment of patients with ALK-positive NSCLC. Treatment with crizotinib results in clinical benefit rate of 85%-90% and a median progression-free survival of 9-10 months for this molecular subset of patients. Ongoing studies will define the impact of crizotinib on overall survival and provide insights into the resistance mechanisms and potential activation of alternate pathways. Heat shock protein 90 inhibitors also appear promising in the treatment of ALK-positive NSCLC patients, based on early results. This article reviews the characteristics, treatment, and ongoing research in patients with ALK-positive NSCLC.

Citing Articles

P40 and TTF-1 double-expressing non-small cell lung cancer with EML4-ALK and PIK3CA gene mutations: A case report and review of the literature.

Cai Y, Liu H, Chen X, Yang J, Huang B Oncol Lett. 2023; 25(2):59.

PMID: 36644157 PMC: 9827448. DOI: 10.3892/ol.2022.13645.

An epigenetic switch regulates the ontogeny of AXL-positive/EGFR-TKi-resistant cells by modulating miR-335 expression.

Safaric Tepes P, Pal D, Lindsted T, Ibarra I, Lujambio A, Jimenez Sabinina V Elife. 2021; 10.

PMID: 34254585 PMC: 8285107. DOI: 10.7554/eLife.66109.

Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR.

Alwithenani A, Bethune D, Castonguay M, Drucker A, Flowerdew G, Forsythe M PLoS One. 2021; 16(5):e0251080.

PMID: 33956842 PMC: 8101740. DOI: 10.1371/journal.pone.0251080.

Systemic therapy for brain metastases.

Rick J, Shahin M, Chandra A, Dalle Ore C, Yue J, Nguyen A Crit Rev Oncol Hematol. 2019; 142:44-50.

PMID: 31357143 PMC: 6746616. DOI: 10.1016/j.critrevonc.2019.07.012.

Frequency of actionable alterations in epidermal growth factor receptor wild type non-small cell lung cancer: experience of the Wide Catchment Area of Romagna (AVR).

Chiadini E, Canale M, Delmonte A, Dazzi C, Casanova C, Capelli L J Thorac Dis. 2018; 10(8):4858-4864.

PMID: 30233859 PMC: 6129926. DOI: 10.21037/jtd.2018.07.22.

References

Shaw A, Yeap B, Mino-Kenudson M, Digumarthy S, Costa D, Heist R . Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009; 27(26):4247-53. PMC: 2744268. DOI: 10.1200/JCO.2009.22.6993. View

Choi Y, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T . EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med. 2010; 363(18):1734-9. DOI: 10.1056/NEJMoa1007478. View

Ambrogio C, Voena C, Manazza A, Martinengo C, Costa C, Kirchhausen T . The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation. Cancer Res. 2008; 68(21):8899-907. PMC: 2596920. DOI: 10.1158/0008-5472.CAN-08-2568. View

Sasaki T, Rodig S, Chirieac L, Janne P . The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer. 2010; 46(10):1773-80. PMC: 2888755. DOI: 10.1016/j.ejca.2010.04.002. View

Koivunen J, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes A . EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008; 14(13):4275-83. PMC: 3025451. DOI: 10.1158/1078-0432.CCR-08-0168. View

Inamura K, Takeuchi K, Togashi Y, Nomura K, Ninomiya H, Okui M . EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol. 2008; 3(1):13-7. DOI: 10.1097/JTO.0b013e31815e8b60. View

Schiller J, Harrington D, Belani C, Langer C, Sandler A, Krook J . Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346(2):92-8. DOI: 10.1056/NEJMoa011954. View

Katayama R, Khan T, Benes C, Lifshits E, Ebi H, Rivera V . Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A. 2011; 108(18):7535-40. PMC: 3088626. DOI: 10.1073/pnas.1019559108. View

Normant E, Paez G, West K, Lim A, Slocum K, Tunkey C . The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. Oncogene. 2011; 30(22):2581-6. DOI: 10.1038/onc.2010.625. View

10.

Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G . The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2007; 8(1):11-23. DOI: 10.1038/nrc2291. View

11.

Sequist L, Gettinger S, Senzer N, Martins R, Janne P, Lilenbaum R . Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol. 2010; 28(33):4953-60. PMC: 4676802. DOI: 10.1200/JCO.2010.30.8338. View

12.

Sakamoto H, Tsukaguchi T, Hiroshima S, Kodama T, Kobayashi T, Fukami T . CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell. 2011; 19(5):679-90. DOI: 10.1016/j.ccr.2011.04.004. View

13.

Takahashi T, Sonobe M, Kobayashi M, Yoshizawa A, Menju T, Nakayama E . Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol. 2010; 17(3):889-97. DOI: 10.1245/s10434-009-0808-7. View

14.

Soda M, Choi Y, Enomoto M, Takada S, Yamashita Y, Ishikawa S . Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007; 448(7153):561-6. DOI: 10.1038/nature05945. View

15.

Rodig S, Mino-Kenudson M, Dacic S, Yeap B, Shaw A, Barletta J . Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 2009; 15(16):5216-23. PMC: 2865649. DOI: 10.1158/1078-0432.CCR-09-0802. View

16.

Inamura K, Takeuchi K, Togashi Y, Hatano S, Ninomiya H, Motoi N . EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol. 2009; 22(4):508-15. DOI: 10.1038/modpathol.2009.2. View

17.

Paik J, Choe G, Kim H, Choe J, Lee H, Lee C . Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J Thorac Oncol. 2011; 6(3):466-72. DOI: 10.1097/JTO.0b013e31820b82e8. View

18.

Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba I . Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005; 97(5):339-46. DOI: 10.1093/jnci/dji055. View

19.

Yi E, Boland J, Maleszewski J, Roden A, Oliveira A, Aubry M . Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol. 2011; 6(3):459-65. DOI: 10.1097/JTO.0b013e318209edb9. View

20.

Soda M, Takada S, Takeuchi K, Choi Y, Enomoto M, Ueno T . A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci U S A. 2008; 105(50):19893-7. PMC: 2605003. DOI: 10.1073/pnas.0805381105. View